Palliative Care: Physician Communication and Patient Comprehension
The consensus from our audience was almost exactly evenly split between discussing palliative care with patients at the beginning of treatment and after all treatment options have failed.<br><br>Recent research, however, suggests that palliative care as a method to ease the symptoms of cancer treatment is most effective at the onset of treatment.
Very few, only 12%, of respondents indicated that patients understand palliative care before it is explained.<br><br>While this is very much in line with the research, experts have indicated the need for increased broad awareness of palliative care in order to increase the effectiveness and decrease misconceptions and fear surrounding this topic.
Almost all respondents, 98.85% see a need for better training for physicians who are discussing palliative care with their patients.<br><br>To read more about palliative care, visit <a href="http://www.cancertherapyadvisor.com/palliative-care/section/2450/">http://www.cancertherapyadvisor.com/palliative-care/section/2450/</a>.
The Palliative Care in Oncology Symposium recently took place in Boston, Massachusetts, and focused on patient-centered care across the cancer continuum.
With this in mind, Cancer Therapy Advisor conducted a community poll that asked our readers about their experience in dealing with issues surrounding the discussion of palliative care with their patients.
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|
|Renal Cell Carcinoma||Regimens||Drugs|
Cancer Therapy Advisor Articles
- BRCA1/Shieldin Double Mutations May Signal Resistance to PARP Inhibitors
- Study Analyzing Postmarketing Data on Breast Implant Safety Sparks FDA Response
- Higher-Dose Immunoglobulin Replacement Therapy in Chronic Lymphocytic Leukemia
- Beyond BRCA: New Predisposition Genes Linked to Breast, Ovarian Cancers
- "Impressive" CNS Responses With Osimertinib Compared With Standard EGFR-TKIs in Patients With CNS Metastases at Baseline
- Despite Promising Trial Results, Skeptics Raise Red Flags About Anlotinib's Efficacy in Heavily Treated NSCLC
- Higher Risk of MGUS in Relatives of Patients With Multiple Myeloma Confirmed
- Brentuximab Vedotin Combo Active in Older Patients With Hodgkin Lymphoma
- Prostate Cancer Drug Resistance Mediated by Epigenetic Changes
- Nilotinib and Dasatinib Confer Similar Outcomes for Chronic-Phase CML